LivaNova (NASDAQ:LIVN) Director Sells $131,538.00 in Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,650 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $79.72, for a total transaction of $131,538.00. Following the transaction, the director owned 7,934 shares of the company’s stock, valued at approximately $632,498.48. This trade represents a 17.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

LivaNova Trading Up 0.9%

LIVN stock opened at $81.92 on Friday. The business’s 50-day moving average is $80.69 and its 200 day moving average is $72.89. LivaNova PLC has a 12-month low of $48.82 and a 12-month high of $85.76. The stock has a market cap of $4.51 billion, a price-to-earnings ratio of 24.24 and a beta of 0.87. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

LivaNova (NASDAQ:LIVN) last released its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The business had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. During the same quarter last year, the business posted $1.05 earnings per share. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, sell-side analysts anticipate that LivaNova PLC will post 3.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LIVN has been the subject of several research reports. Mizuho upped their price objective on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a research report on Wednesday, August 5th. Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. Needham & Company LLC lifted their target price on shares of LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, KeyCorp boosted their target price on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, June 22nd. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and a consensus price target of $84.12.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently modified their holdings of the business. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in LivaNova in the 2nd quarter valued at about $4,053,000. California State Teachers Retirement System boosted its stake in LivaNova by 7,996.3% during the second quarter. California State Teachers Retirement System now owns 5,154,505 shares of the company’s stock worth $423,855,000 after buying an additional 5,090,840 shares during the period. Turner Financial Group Inc. purchased a new position in shares of LivaNova during the 2nd quarter worth approximately $392,000. Public Employees Retirement System of Ohio acquired a new stake in LivaNova in the 2nd quarter valued at approximately $37,000. Finally, GAMMA Investing LLC raised its position in LivaNova by 18.2% in the second quarter. GAMMA Investing LLC now owns 1,838 shares of the company’s stock valued at $151,000 after purchasing an additional 283 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.